Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Daniel Resende Faleiros, Juliana Alvares-Teodoro, Everton Nunes da Silva, Brian B. Godman, Ramon Gonçalves Pereira, Eli Iola Gurgel Andrade, Francisco A. Acurcio, Augusto A. Guerra Júnior

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Budget Impact Analyses (BIA) of medicines helps managers in promoting health systems’ sustainability when assessing the role and value of new medicines. However, it is not clear whether BIAs typically underestimate or overestimate the impact on real-world budgets. This retroactive analysis seeks to compare estimated values obtained by a BIA and Real-World Evidence (RWE) to guide discussions. Methods: The estimated values were obtained through a BIA concerning the incorporation of adalimumab for the treatment of Rheumatoid Arthritis into the Brazilian Unified Health System (SUS) carried out retroactively and per international guidelines. RWE data was extracted from SUS computerized systems. We subsequently compared the number of treatments, costs, and Incremental Budget Impact (IBI). Results–The total number of treatments was underestimated by 10% (6,243) and the total expenditure was overestimated by 463% (US$ 4.7 billion). In five years, the total difference between the estimated values and real IBI reached US$ 1.1 billion. A current expenditure of US$ 1.0 was observed for every US$ 5.60 of estimated expenditure. Conclusion–The higher estimates from the BIA might cause decision makers to be more cautious with the introduction of a new medicine to reduce the opportunity costs for other interventions.

Original languageEnglish
Number of pages28
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Early online date27 May 2021
DOIs
Publication statusE-pub ahead of print - 27 May 2021

Keywords

  • budget impact analyses
  • Brazil
  • real world evidence

Fingerprint

Dive into the research topics of 'Budget impact analysis of medicines: estimated values versus real-world evidence and the implications'. Together they form a unique fingerprint.

Cite this